This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Incyte Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations by Charles Evans in Dermatological Treatments
Introduction
Charles Evans is a notable inventor based in Guildford, GB. He has made significant contributions to the field of dermatology through his innovative work on topical formulations for treating various skin diseases. His expertise and dedication to improving patient care are evident in his patented inventions.
Latest Patents
Charles Evans holds a patent for "Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases." This patent focuses on the development of topical formulations that include a JAK 1/2 inhibitor, specifically ruxolitinib, or its pharmaceutically acceptable salts. The formulations are designed to treat a range of skin diseases, including psoriasis, atopic dermatitis, alopecia, vitiligo, and several others. The inclusion of an organic amine pH adjusting agent, which can be a tertiary amine or an alkanol amine, enhances the effectiveness of the treatment.
Career Highlights
Charles Evans is associated with Incyte Corporation, where he continues to work on innovative solutions for skin diseases. His commitment to research and development has led to advancements in dermatological treatments, benefiting many patients suffering from chronic skin conditions.
Collaborations
Charles has collaborated with talented coworkers, including Florencia Guidali and Tecashanell McIntosh. Their combined efforts contribute to the ongoing research and development of effective treatments in the field of dermatology.
Conclusion
Charles Evans is a distinguished inventor whose work in dermatological formulations has the potential to transform the treatment of various skin diseases. His innovative approach and dedication to improving patient outcomes are commendable.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
